Jeffrey K Harrison
Overview
Explore the profile of Jeffrey K Harrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anderson H, Takacs G, Harrison J, Rong L, Stepien T
J Theor Biol
. 2024 Sep;
595:111951.
PMID: 39307417
The immune checkpoint inhibitor anti-PD-1, commonly used in cancer immunotherapy, has not been successful as a monotherapy for the highly aggressive brain cancer glioblastoma. However, when used in conjunction with...
2.
Takacs G, Garcia J, Hodges C, Kreiger C, Sherman A, Harrison J
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272914
Glioblastoma (GBM) is the most common malignant primary brain tumor, resulting in poor survival despite aggressive therapies. GBM is characterized by a highly heterogeneous and immunosuppressive tumor microenvironment (TME) made...
3.
Anderson H, Takacs G, Harrison J, Rong L, Stepien T
bioRxiv
. 2024 Aug;
PMID: 39185154
The immune checkpoint inhibitor anti-PD-1, commonly used in cancer immunotherapy, has not been successful as a monotherapy for the highly aggressive brain cancer glioblastoma. However, when used in conjunction with...
4.
Littrell C, Takacs G, Sankara C, Sherman A, Rubach K, Garcia J, et al.
J Control Release
. 2024 Aug;
374:181-193.
PMID: 39103055
The focus of nanoparticles in vivo trafficking has been mostly on their tissue-level biodistribution and clearance. Recent progress in the nanomedicine field suggests that the targeting of nanoparticles to immune...
5.
Takacs G, Garcia J, Hodges C, Kreiger C, Sherman A, Harrison J
bioRxiv
. 2024 Jun;
PMID: 38895268
Glioblastoma (GBM) is the most common malignant primary brain tumor, resulting in poor survival despite aggressive therapies. GBM is characterized by a highly heterogeneous and immunosuppressive tumor microenvironment (TME) made...
6.
Chakraborty A, Yang C, Kresak J, Silver A, Feier D, Tian G, et al.
Cells
. 2024 Jun;
13(11.
PMID: 38891070
Glioblastoma (GBM) poses a significant challenge in clinical oncology due to its aggressive nature, heterogeneity, and resistance to therapies. Cancer stem cells (CSCs) play a critical role in GBM, particularly...
7.
Chakraborty A, Yang C, Kresak J, Silver A, Feier D, Tian G, et al.
bioRxiv
. 2024 Mar;
PMID: 38501121
Glioblastoma (GBM) poses a significant challenge in clinical oncology due to its aggressive nature, heterogeneity, and resistance to therapies. Cancer stem cells (CSCs) play a critical role in GBM, particularly...
8.
Law M, Dulloo Z, Eggleston S, Takacs G, Alexandrow G, Wang M, et al.
bioRxiv
. 2024 Mar;
PMID: 38496520
New agents are needed that selectively kill cancer cells without harming normal tissues. The TRAIL ligand and its receptors, DR5 and DR4, exhibit cancer-selective toxicity, but TRAIL analogs or agonistic...
9.
Anderson H, Takacs G, Harris D, Kuang Y, Harrison J, Stepien T
J Math Biol
. 2023 Dec;
88(1):10.
PMID: 38099947
Glioblastoma (GBM) is an aggressive primary brain cancer that currently has minimally effective treatments. Like other cancers, immunosuppression by the PD-L1-PD-1 immune checkpoint complex is a prominent axis by which...
10.
Takacs G, Kreiger C, Luo D, Tian G, Garcia J, Deleyrolle L, et al.
Front Immunol
. 2023 Jan;
13:993444.
PMID: 36685592
Glioblastoma (GBM) is the most common and malignant primary brain tumor, resulting in poor survival despite aggressive therapies. GBM is characterized in part by a highly heterogeneous and immunosuppressive tumor...